読み込み中
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
終値時点
$5.31
−$0.01 · -0.19%
時間外
$5.31
$0.00 · 0.00%
10月8日 16:15 ET
日中の時刻はETです。市場データは遅延する場合があります。
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
日中レンジ
現在 $5.31
52週レンジ
現在 $5.31
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
45
適正価値
センチメント
62
強気
リスク
80
高リスク
モメンタム
38
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
日中レンジ
現在 $5.31
52週レンジ
現在 $5.31
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 218.6万 USD | 394.5万 USD | 1552.9万 USD | 1390.7万 USD | 435.9万 USD |
| 売上原価 | 93万 USD | — | — | — | — |
| 粗利益 | 125.6万 USD | 394.5万 USD | 1552.9万 USD | 1390.7万 USD | 435.9万 USD |
| 研究開発 | 6945.3万 USD | 7026.9万 USD | 7304万 USD | 8507.7万 USD | 1.04億 USD |
| 販売・一般管理 | 2071.8万 USD | 2283万 USD | 3061.6万 USD | 2641万 USD | 2852.7万 USD |
| 営業費用 | 8924.1万 USD | 9309.9万 USD | 1.04億 USD | 1.11億 USD | 1.33億 USD |
| 受取利息 | 216.4万 USD | 167万 USD | 124.3万 USD | 164万 USD | 13.2万 USD |
| 減価償却費と償却費 | 93万 USD | 262.2万 USD | 306.9万 USD | 367.5万 USD | 377.8万 USD |
| 営業利益 | −8798.5万 USD | −8915.4万 USD | −8812.7万 USD | −9758万 USD | −1.28億 USD |
| 純利益 | −2419.3万 USD | −1.31億 USD | −8767.9万 USD | −9604.6万 USD | −1.28億 USD |
会社概要が更新されました 2026年10月8日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI75.46万0.00%2.3兆 USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF27.41万0.00%954億 USD0.05%$233.13-0.15%
iShares Micro-Cap ETFIWC8.28万0.01%13.33億 USD0.60%$182.79-0.31%
U.S. Micro Cap Portfolio ETFDFMC4.43万0.00%75.2億 USD0.43%$57.70+0.35%
Dimensional - US Small Cap ETFDFAS3.4万0.00%336.6億 USD0.31%$78.10+0.23%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.11万0.00%61.57億 USD0.26%$68.11+0.22%
Dimensional - US Core Equity 2 ETFDFAC9868.60.00%882.76億 USD0.21%$45.11-0.15%
Avantis U.S. Small Cap Equity ETFAVSC7591.64—30.38億 USD0.25%$69.96+0.47%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACAvantis U.S. Small Cap Equity ETFAVSCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
